UDG Healthcare acquires Incisive Health and Putnam Associates
Category: #health  By Mateen Dalal  Date: 2019-05-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

UDG Healthcare acquires Incisive Health and Putnam Associates
  • Both acquisitions are good cultural & strategic fit and meet the company’s financial hurdle rates while further expanding its current capabilities.
  • UDG would be financing both transactions from its existing cash & debt facilities.

UDG Healthcare plc, (UDG), a leading Ireland-based healthcare advisory service provider, has reportedly announced that it has acquired American healthcare consultancy, Putnam Associates (Putnam) and British healthcare policy & communications consultancy, Incisive Health (Incisive).

Reports cite, the two transactions would be significantly strengthening UDG’s Ashfield Communications & Advisory business. The two acquisitions would be for a combined consideration of approximately $106 million with Putnam costing $88.6 million and Incisive costing $17.7 million.

According to a report by Pharmafield, the Putnam acquisition would be consolidating Ashfield’s growing advisory pillar by introducing significant expertise in product pricing, commercialization, reimbursement as well as market access strategy. Meanwhile, the Incisive acquisition would be adding specialist capability in the public health advocacy domain, supporting clients in obtaining a secure marketing access for their respective brands alongside broader communication services.

The Putnam deal would see an upfront payment of $60 million in addition to a $20.1 million earn-out for over three years along with a further $8.5 million five year earn-out. The Incisive deal would be seeing an initial consideration of approximately $10.4 million with a $7.3 million earn-out that would be payable over a three-year period.

The CEO of UDG Healthcare, Brendan McAtamney stated that the company is thrilled to announce the acquisition, which would be further enhancing the capabilities of its Ashfield Communications & Advisory. McAtamney further added that both Putnam and Incisive acquisitions are a good cultural & strategic fit for the company and meet its target financial-hurdle rates while also expanding its present capabilities.

According to reports, UDG would be financing both the transactions from its existing cash & debt facilities. The transactions are expected to provide a return on capital that is employed in excess of the company’s 15% target within three years.

Source Credit:

https://www.udghealthcare.com/media/press-releases/udg-healthcare-significantly-strengthens-its-ashfield-communications-and-advisory-business-with-two-acquisitions-for-a-combined-consideration-of-up-to-106-million

https://pharmafield.co.uk/pharma_news/udg-healthcare-acquires-putnam-associates-and-incisive-health/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

MoA Technology targets herbicide resistance crisis & raises $8 million
MoA Technology targets herbicide resistance crisis & raises $8 million
By Mateen Dalal

MoA Technology has created three platforms: MoA SELECTTM, MoA TARGETTM and MoA GALAXYTM, which would work together for effective herbicide creation.   MoA Technology is borne out of Oxford University research is aimed at inhibiting herbicide...

Trump refuses to forge deals with Huawei citing national security
Trump refuses to forge deals with Huawei citing national security
By Mateen Dalal

Donald Trump declares the business with Huawei as a national threat and hence forth has declined all the business opportunities with the company.   The existing contract of the Commerce Department is expected to end sooner. The United Stat...

Trovagene to unveil key study data at APAC Prostate Cancer Conference
Trovagene to unveil key study data at APAC Prostate Cancer Conference
By Mateen Dalal

Data from the Phase 2 Onvansertib clinical trial will be presented at the 20th Prostate Cancer Conference.   The trial assesses the efficacies of Onvansertib on patients with Metastatic Castration-Resistant Prostate Cancer. Trovagene, a cl...